Literature DB >> 21279817

Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.

Shuji Ozaki1,2,3, Takeshi Harada4,5, Shiro Fujii4,5, Shingen Nakamura4,5, Hirokazu Miki4,5, Ayako Nakano4,5, Kumiko Kagawa4,5, Kyoko Takeuchi4,5, Masahiro Abe4,5, Toshio Matsumoto4,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21279817     DOI： 10.1007/s12185-011-0775-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

1.  Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma.

Authors:  Shinsuke Iida; Takaaki Chou; Shinichiro Okamoto; Hirokazu Nagai; Kiyohiko Hatake; Hirokazu Murakami; Toshiyuki Takagi; Kazuyuki Shimizu; Henry Lau; Kenichi Takeshita; Masaaki Takatoku; Tomomitsu Hotta
Journal:  Int J Hematol       Date:  2010-06-18       Impact factor: 2.490

Review 2.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

3.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

4.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Authors:  Donna M Weber; Christine Chen; Ruben Niesvizky; Michael Wang; Andrew Belch; Edward A Stadtmauer; David Siegel; Ivan Borrello; S Vincent Rajkumar; Asher Alban Chanan-Khan; Sagar Lonial; Zhinuan Yu; John Patin; Marta Olesnyckyj; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

5.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Authors:  Meletios Dimopoulos; Andrew Spencer; Michael Attal; H Miles Prince; Jean-Luc Harousseau; Anna Dmoszynska; Jesus San Miguel; Andrzej Hellmann; Thierry Facon; Robin Foà; Alessandro Corso; Zvenyslava Masliak; Marta Olesnyckyj; Zhinuan Yu; John Patin; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

6.  Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Bang-Ning Lee; Ellen J Schlette; Susan M O'Brien; Hui Gao; Sijin Wen; William G Wierda; Zeev Estrov; Stefan Faderl; Evan N Cohen; Changping Li; James M Reuben; Michael J Keating
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

7.  Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis.

Authors:  Jing Yang; Michele Wezeman; Xiang Zhang; Pei Lin; Michael Wang; Jianfei Qian; Bo Wan; Larry W Kwak; Long Yu; Qing Yi
Journal:  Cancer Cell       Date:  2007-09       Impact factor: 31.743

8.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors:  S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal:  Lancet Oncol       Date:  2009-10-21       Impact factor: 41.316

9.  Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.

Authors:  Georg Aue; Ndegwa Njuguna; Xin Tian; Susan Soto; Thomas Hughes; Berengere Vire; Keyvan Keyvanfar; Federica Gibellini; Janet Valdez; Carol Boss; Leigh Samsel; J Philip McCoy; Wyndham H Wilson; Stefania Pittaluga; Adrian Wiestner
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941
  9 in total
  3 in total

1.  Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.

Authors:  Yasuyoshi Morita; Takahiro Shimada; Terufumi Yamaguchi; Shinya Rai; Chikara Hirase; Masakatsu Emoto; Kentaro Serizawa; Yasuhiro Taniguchi; Mayuko Ojima; Yoichi Tatsumi; Takashi Ashida; Itaru Matsumura
Journal:  Int J Hematol       Date:  2011-11-30       Impact factor: 2.490

2.  Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.

Authors:  Isabelle Krämer; Melanie Engelhardt; Sabrina Fichtner; Brigitte Neuber; Sergej Medenhoff; Uta Bertsch; Jens Hillengass; Marc-Steffen Raab; Dirk Hose; Anthony D Ho; Hartmut Goldschmidt; Michael Hundemer
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

3.  Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.

Authors:  Takeshi Harada; Shuji Ozaki; Asuka Oda; Shiro Fujii; Shingen Nakamura; Hirokazu Miki; Kumiko Kagawa; Kyoko Takeuchi; Toshio Matsumoto; Masahiro Abe
Journal:  Int J Hematol       Date:  2013-04-23       Impact factor: 2.490
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.